- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Brain Cancer | Clinical
Gender-Specific AI Model Advances Understanding of Glioblastoma Progression and Treatment Response
September 21, 2022
Distinguishing on current imaging between disease progression and pseudo progression in patients with glioblastoma is one of the most difficult clinical problems, according to Manmeet Ahluwalia, MD and Pallavi Tiwari, PhD.
Promising Safety and Efficacy Seen With Higher-Dose Rhenium-186 Nanoliposome in Recurrent Glioma
September 09, 2022
Rhenium-186 nanoliposome at doses exceeding 100 Gy showed promising results in patients with recurrent glioma, according to phase 1 findings from the ReSPECT-GBM trial presented at ESMO 2022.
Paxalisib Plus Radiotherapy Reveals Promising ORR in Patients With Brain Metastases
August 08, 2022
The combination of paxalisib and radiotherapy exhibited complete or partial responses in all patients with brain metastases, according to interim data from an ongoing phase I clinical trial.
FDA Grants Orphan Drug Designation to DSP-0390 in Brain Cancer
July 18, 2022
An orphan drug designation has been granted to DSP-0390 by the FDA as treatment in patients with brain cancer.
FDA Grants Orphan Drug Designation to NT-I7 for Glioblastoma Multiforme
July 13, 2022
Orphan drug designation has been granted to NT-I7 by the FDA for patients with glioblastoma multiforme.
FDA Grants Orphan Drug and Fast Track Designations to Sonodynamic Therapy in Brain Cancers
July 13, 2022
An orphan drug designation and a fast track designation have been granted by the FDA to a novel sonodynamic therapy platform as a potential treatment for patients with recurrent glioblastoma and other malignant gliomas.
FDA Grants RPDD to Paxalisib for Rare Pediatric Brain Cancer
July 06, 2022
Rare pediatric disease designation has been awarded to paxalisib for the treatment of patients with atypical rhabdoid or teratoid tumors in rare and highly-aggressive childhood brain cancer.
Long-Term Survival Possible With Vincristine Plus Radiotherapy in Anaplastic Oligodendroglial Tumors
June 30, 2022
Findings from 2 studies suggest that long-term survival is possible in a significant proportion of patients with a 1p/19q co-deleted oligodendroglioma.
FDA Grants Orphan Drug Designation to VBI-1901 for Patients Treatment of Glioblastoma
June 23, 2022
An investigational bivalent gB/pp65 immunotherapeutic vaccine candidate has been granted orphan drug designation by the FDA for the treatment of patients with glioblastoma.
FDA Grants Fast Track Status to Dianhydrogalactitol for Newly-Diagnosed Glioblastoma
June 20, 2022
Fast track designation has been granted by the FDA to dianhydrogalactitol for the treatment of patients with newly-diagnosed unmethylated glioblastoma.